Ana Ferreirinha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Ana Ferreirinha has a total of 34 co-authors. Here are the top co-authors by number of shared publications:
- Maria Cristina Fialho
Department of Dermatovenereology, Santo António dos Capuchos Hospital, Unidade Local de Saúde de São José, Lisbon, Portugal
4 shared publications A.L. João
Dermatology and Venereology Department, Hospital de Santo António dos Capuchos, Centro Hospitalar Universitário de Lisboa Central, Alameda Santo António dos Capuchos, 1169-050, Lisbon, Portugal
2 shared publications- Joana Bártolo
Melanoma and Sarcoma Unit Department of Surgery Instituto Português de Oncologia de Lisboa Francisco Gentil EPE Lisbon Portugal
2 shared publications Joana Cabete
2 shared publicationsPedro Simões-Farinha
2 shared publicationsV. Farricha
General Surgery Department, Instituto Português de Oncologia de Lisboa, Rua Prof. Lima Basto, 1099-023 Lisbon, Portugal
2 shared publications
Latest Publications
- 12 November 2026
- Published by Instituto Mexicano del Seguro Social in Portuguese Journal of Dermatology and Venereology
Lebrikizumab for difficult-to-treat atopic dermatitis in a Portuguese cohort
The full content will be available shortly. Thank you for your patience!
- 12 November 2026
- Published by Instituto Mexicano del Seguro Social in Portuguese Journal of Dermatology and Venereology
Lebrikizumab for difficult-to-treat atopic dermatitis in a Portuguese cohort
The full content will be available shortly. Thank you for your patience!
- 29 October 2026
- Published by Instituto Mexicano del Seguro Social in Portuguese Journal of Dermatology and Venereology
Utilization patterns and perceptions of artificial intelligence among portuguese dermatovenereologists
The full content will be available shortly. Thank you for your patience!
- 29 October 2026
- Published by Instituto Mexicano del Seguro Social in Portuguese Journal of Dermatology and Venereology
Utilization patterns and perceptions of artificial intelligence among portuguese dermatovenereologists
The full content will be available shortly. Thank you for your patience!
- Open Access
- 6 May 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (3) , 501362
Eosinophilic annular erythema in a patient with hepatitis B-related cirrhosis
- 6 May 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (3) , 501362
Open AccessEosinophilic annular erythema in a patient with hepatitis B-related cirrhosis
- Open Access
- 19 February 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 101 (1)
Pitiríase rubra pilar tipo IV tratada com ixequizumabe
- 19 February 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia (Versão em Português)
- Vol. 101 (1)
Open AccessPitiríase rubra pilar tipo IV tratada com ixequizumabe
- Open Access
- 14 January 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (1) , 501283
Type IV pityriasis rubra pilaris treated with ixekizumab
- 14 January 2026
- Published by Elsevier in Anais Brasileiros de Dermatologia
- Vol. 101 (1) , 501283
Open AccessType IV pityriasis rubra pilaris treated with ixekizumab
- Open Access
- 15 December 2025
- Published by Instituto Mexicano del Seguro Social in Portuguese Journal of Dermatology and Venereology
- Vol. 83 (4)
Real-world efficacy and safety of risankizumab in moderate-to-severe psoriasis: experience from a tertiary center
Objectives: To assess the real-world effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis, including special area involvement. Methods: A retrospective cohort study was conducted in a Portuguese tertiary hospital, including adult patients with moderate-to-severe psoriasis treated with risankizumab for at least 16 weeks. Clinical assessments were performed at weeks 16 and ≥ 52. Efficacy was measured by PASI-75, PASI-90, and PASI-100 responses. Safety was evaluated based on reported adverse events (AE) and treatment discontinuations. Results: A total of 114 patients were included, 63.2% male, with a median age of 50 years and a median disease duration of 16 years. The median number of comorbidities per patient was 2. At week 16, PASI-90 and PASI-100 were achieved by 71.3% and 61.4%, respectively. At ≥ 52 weeks, PASI-90 was achieved by 86.6% and PASI-100 by 79.4%. Complete resolution was observed in 95.2% of scalp psoriasis, 88.5% of nail psoriasis, and 54.5% of palmoplantar psoriasis cases. Psoriatic arthritis resolved completely in 67.7% of cases. Three malignancies were reported without an established causal relationship to risankizumab. Overall, 12.3% discontinued treatment, most due to primary or secondary efficacy failure. No other AEs were reported. Conclusion: Risankizumab demonstrated high effectiveness and a favorable safety profile in a real-world setting, with robust short-and long-term outcomes, including in special areas and psoriatic arthritis. These findings support its use in routine clinical practice. Further real-world studies with comparators are warranted.
- 15 December 2025
- Published by Instituto Mexicano del Seguro Social in Portuguese Journal of Dermatology and Venereology
- Vol. 83 (4)
Open AccessReal-world efficacy and safety of risankizumab in moderate-to-severe psoriasis: experience from a tertiary center
Objectives: To assess the real-world effectiveness and safety of risankizumab in patients with moderate-to-severe psoriasis, including special area involvement. Methods: A retrospective cohort study was conducted in a Portuguese tertiary hospital, including adult patients with moderate-to-severe psoriasis treated with risankizumab for at least 16 weeks. Clinical assessments were performed at weeks 16 and ≥ 52. Efficacy was measured by PASI-75, PASI-90, and PASI-100 responses. Safety was evaluated based on reported adverse events (AE) and treatment discontinuations. Results: A total of 114 patients were included, 63.2% male, with a median age of 50 years and a median disease duration of 16 years. The median number of comorbidities per patient was 2. At week 16, PASI-90 and PASI-100 were achieved by 71.3% and 61.4%, respectively. At ≥ 52 weeks, PASI-90 was achieved by 86.6% and PASI-100 by 79.4%. Complete resolution was observed in 95.2% of scalp psoriasis, 88.5% of nail psoriasis, and 54.5% of palmoplantar psoriasis cases. Psoriatic arthritis resolved completely in 67.7% of cases. Three malignancies were reported without an established causal relationship to risankizumab. Overall, 12.3% discontinued treatment, most due to primary or secondary efficacy failure. No other AEs were reported. Conclusion: Risankizumab demonstrated high effectiveness and a favorable safety profile in a real-world setting, with robust short-and long-term outcomes, including in special areas and psoriatic arthritis. These findings support its use in routine clinical practice. Further real-world studies with comparators are warranted.
- Open Access
- 9 December 2025
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 117 (3) , 104529
Eruptive Verrucous Keratoses and Melanocytic Nevi Induced by Encorafenib Plus Cetuximab in a Patient With Metastatic Colorectal Cancer
- 9 December 2025
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 117 (3) , 104529
Open AccessEruptive Verrucous Keratoses and Melanocytic Nevi Induced by Encorafenib Plus Cetuximab in a Patient With Metastatic Colorectal Cancer
- Open Access
- 19 September 2025
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 116 (10) , T1116-T1122
[Artículo traducido] Diagnóstico de melanoma con fotografía corporal total en 3D
- 19 September 2025
- Published by Elsevier in Actas Dermo-Sifiliograficas
- Vol. 116 (10) , T1116-T1122
Open Access[Artículo traducido] Diagnóstico de melanoma con fotografía corporal total en 3D
- 19 May 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (5) , 654-655
Isolierte Extremitätenperfusion als gliedmaßenerhaltende Therapie bei lokal fortgeschrittenem Plattenepithelkarzinom
- 19 May 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (5) , 654-655
Isolierte Extremitätenperfusion als gliedmaßenerhaltende Therapie bei lokal fortgeschrittenem Plattenepithelkarzinom
- 21 March 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (5) , 654-655
Isolated limb perfusion as a limb‐saving therapy for locally advanced squamous cell carcinoma
- 21 March 2025
- Published by Wiley in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
- Vol. 23 (5) , 654-655
Isolated limb perfusion as a limb‐saving therapy for locally advanced squamous cell carcinoma